Aim Rule 26

AIM Rule 26

The following information is disclosed in accordance with Rule 26 of the AIM regulations on the London Stock Exchange.

Please note the company changed name from Retroscreen Virology to hVIVO in April 2015, so many of the historical documents here will refer to Retroscreen Virology.

Description of the business

hVIVO is a rapidly growing UK life sciences company pioneering a technology platform which uses human models of disease to study new drugs and investigate disease in a safe, controlled environment.

hVIVO has established itself as the world leader in this field through the provision of clinical services to third party study sponsors. To date, the Company has conducted over 48 clinical studies, involving more than 2,300 volunteers for a range of leading industry, governmental and academic clients. However, the hVIVO platform has a much wider application in helping to understand illness better because the Company believes that the best way to understand human disease is by studying it in humans, not laboratory models.

Directors and committees

Click here for more information about the Directors.
Click here for more information about the Audit Committee.
Click here for more information about the Remuneration Committee

Country of incorporation and main country of operation

hVIVO plc (formerly Retroscreen Virology Group plc) is incorporated in England and Wales (Registration number 08008725). All operations are carried out within the United Kingdom.

Current constitutional documents

Articles of Association 

Securities in issue

Click here for more information about number of securities in issue and, insofar as the Company is aware, the percentage of AIM securities not in public hands, together with the identity and percentage of significant shareholders.

UK City Code on Takeovers and Mergers

hVIVO is subject to the provisions of the UK City Code on Takeovers and Mergers.

Principles of Corporate Governance

hVIVO’s Board recognises the importance of good corporate governance not only in the areas of accountability and risk management, but also in enhancing and protecting shareholder value. The Company considers the UK Corporate Governance Code (the “Code”) as a basis for guiding its governance structures. However, it is recognised that some aspects of the Code are not relevant for AIM companies such as hVIVO. The Board seeks to comply with the principles of the Quoted Companies Alliance Corporate Governance Code (the “QCA Code”), which is more applicable for small and medium-sized companies listed on AIM.

Financial reports

Click here for access to the Company’s Annual and Half-yearly Reports.

Company announcements

Click here to access notifications made by the Company in the last 12 months.

Admission Document and Circulars

Click here to access the Circular, dated 26 November 2015, for Placing of 9,111,111 new Ordinary Shares at 225 pence per share
Click here to access the Circular, dated 14 August 2014, for Placing of 12,923,077 new Ordinary Shares at 260 pence per share
Click here to access the Circular, dated 14 June 2013, for Placing of 12,750,000 new Ordinary Shares at 200 pence per share.
Click here to access the Admission Document in respect of admission to AIM on 3rd May 2012.


Click here for details of the Company’s advisers.

Get in touch

Give us a call, or drop us an email. We'd love to hear from you!

Get in touch now